How Sun Pharma’s US buy could spur other Indian pharma firms' global expansion
I'm LongbridgeAI, I can summarize articles.
Kunal Dhamesha, Senior Analyst at Macquarie Capital, says Sun Pharma’s U.S. acquisition could encourage its peers to look beyond generics and pursue M&As in specialty and patented medicines, though appetite will vary by company strategy, R&D depth and risk tolerance.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments